Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff
Pathologists can reproducibly score HER2-low and HER2-ultralow when supported by training. Findings may aid decision-making for patients with breast cancer who are potentially eligible for HER2-directed therapy.
Authors
- Marietta Scott (ORCID: https://orcid.org/0000-0002-6894-3561)
- Tsuyoshi Matsuo
- Jessica Whiteley (ORCID: https://orcid.org/0000-0002-3411-014X)
- Michel E. Vandenberghe
- Craig Barker (ORCID: https://orcid.org/0000-0003-2104-016X)
- Agata Wróbel
- Frances M. Jones
- Anne-Marie Boothman
Institutions
- AstraZeneca (United Kingdom) (GB)
Publication Details
- Journal
- Diagnostic Pathology
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1186/s13000-025-01624-3
- Citations
- 6
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 6.27
Funders
- AstraZeneca
- Daiichi Sankyo Europe